FSGS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 原发性FSGS是儿童和成人终末期肾病（ESRD）的主要原因，50%的患者在10年内肾功能丧失。 FSGS临床试验由NIH赞助，以应对这种不良预后和对严格测试的治疗方式的需求。FSGS临床试验是一项III期随机试验，在北美100多个地点对2至40岁的儿童和年轻人进行。入选标准包括活检证实的原发性FSGS、皮质类固醇抵抗（在最小累积剂量为56 mg/kg泼尼松或等效剂量的泼尼松治疗期间，Up/c比值< 1.0）、持续性蛋白尿（Up/c比值> 1.0）和估计的GFR？40 ml/min/1.73m2。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary FSGS is a leading cause of end stage renal disease (ESRD) in both children and adults, with loss of kidney function in 50% of patients over 10-years. The FSGS Clinical Trial was sponsored by the NIH in response to this poor prognosis and the need for rigorously tested treatment modalities. The FSGS Clinical Trial is a Phase III randomized trial of children and young adults age 2 to 40 years being conducted at over 100 sites in North America. Eligibility criteria include biopsy-confirmed primary FSGS, corticosteroid resistance (Up/c ratio < 1.0 during min 4 wks prednisone therapy with cumulative minimal dose of 56 mg/kg prednisone or equivalent), persistent proteinuria (Up/c ratio > 1.0), and an estimated GFR ? 40 ml/min/1.73m2.